Analyst
Stifel
Equibles does not estimate personal net worth.
Paul Matisse is recorded as Analyst at Stifel. Paul Matisse has spoken on 5 earnings calls and 1 other investor event across 5 companies, most recently for Biomarin Pharmaceutical Inc on November 2, 2026. Those appearances were for Neurocrine Biosciences Inc (NBIX), Biomarin Pharmaceutical Inc (BMRN), Acumen Pharmaceuticals, Inc. (ABOS), Denali Therapeutics Inc. (DNLI) and Biogen Inc. (BIIB). The companies whose calls Paul Matisse spoke on are classified in the Healthcare sector.
“I wanted to ask a couple on BMN 333 data next year. Understanding that your thesis here is that you could show clinical superiority, I was wondering what would be an outcome next year that would definitively de-risk that profile and make you confident in going that path for a pivotal study.”
“Obviously, it's been discussed in the media and the press related to its safety profile. I was curious from your perspective, are you comfortable that going forward in the next set of quarters that VICAT will continue to be sort of a resilient grower?”
“So on the EPD profile, we were wondering what's the TPP here? You know, so like what dosing frequency would you like to see, as well as maybe, like, how quickly do you think you can get data from inpatients following that mid-2027 IND filing?”
“I guess taking a step back, given everything you kind of understand around this patient population, the degree to which families are plugged in and we're waiting for Avalaia, Do you think you're seeing a bolus right now?”
Stifel
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
BIIB
Drug Manufacturers - General · Healthcare
